Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
8 studies found for:    baricitinib | Phase 2, 3
Show Display Options
Rank Status Study
1 Recruiting A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA)
Condition: Rheumatoid Arthritis
Interventions: Drug: Baricitinib;   Drug: Placebo
Phase: Phase 3
Sponsor: Eli Lilly and Company
Study Start: October 2014
Primary Completion: March 2017
2 Active, not recruiting A Study in Participants With Moderate to Severe Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Interventions: Drug: Baricitinib;   Drug: Methotrexate;   Drug: Placebo;   Drug: Folic Acid
Phase: Phase 3
Sponsor: Eli Lilly and Company
Study Start: November 2012
Primary Completion: February 2015
3 Active, not recruiting A Study in Moderate to Severe Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Interventions: Drug: Placebo;   Drug: Adalimumab;   Drug: Baricitinib
Phase: Phase 3
Sponsor: Eli Lilly and Company
Study Start: October 2012
Primary Completion: March 2015
4 Recruiting An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Interventions: Drug: Baricitinib;   Drug: Placebo
Phase: Phase 3
Sponsor: Eli Lilly and Company
Study Start: June 2013
Primary Completion: December 2020
5 Completed A Moderate to Severe Rheumatoid Arthritis Study
Condition: Rheumatoid Arthritis
Interventions: Drug: Placebo;   Drug: Baricitinib
Phase: Phase 3
Sponsor: Eli Lilly and Company
Study Start: January 2013
Primary Completion: June 2014
6 Completed A Study in Moderate to Severe Rheumatoid Arthritis Participants
Condition: Rheumatoid Arthritis
Interventions: Drug: Placebo;   Drug: Baricitinib
Phase: Phase 3
Sponsor: Eli Lilly and Company
Study Start: December 2012
Primary Completion: September 2014
7 Completed A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
Condition: Diabetic Kidney Disease
Interventions: Drug: baricitinib;   Drug: Placebo
Phase: Phase 2
Sponsor/Collaborators: Eli Lilly and Company;   Incyte Corporation
Study Start: August 2012
Primary Completion: September 2014
8 Completed A Study in Participants With Rheumatoid Arthritis on Background Methotrexate Therapy
Condition: Arthritis, Rheumatoid
Interventions: Drug: LY3009104;   Drug: Placebo
Phase: Phase 2
Sponsor/Collaborators: Eli Lilly and Company;   Incyte Corporation
Study Start: October 2010
Primary Completion: December 2011

Indicates status has not been verified in more than two years